FAAH and secondary hypertension: In our recent study [16], in which BP was determined with the tail-cuff method only, a 2-week administration of the FAAH inhibitor URB597 did not affect BP and HR in SHR, but reduced BP in the deoxycorticosterone acetate (DOCA)-salt model of secondary hypertension [16].